Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2241058/ligand-pharmaceuticals-lgnd-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2241058
Mar 14, 2024 - Ligand Pharmaceuticals (LGND) reachead $71.93 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close.
0
Ligand Pharmaceuticals (LGND) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2221375/ligand-pharmaceuticals-lgnd-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2221375
Feb 05, 2024 - In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $74.72, denoting a +0.24% change from the preceding trading day.
0
Ligand Pharmaceuticals (LGND) Suffers a Larger Drop Than the General Market: Key Insights
https://www.zacks.com/stock/news/2209178/ligand-pharmaceuticals-lgnd-suffers-a-larger-drop-than-the-general-market-key-insights?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2209178
Jan 11, 2024 - Ligand Pharmaceuticals (LGND) closed at $72.19 in the latest trading session, marking a -1.84% move from the prior day.
0
Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel
https://www.zacks.com/stock/news/2207168/ligand-lgnd-up-9-on-fda-nod-for-molluscum-infection-gel?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207168
Jan 08, 2024 - Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.
0
Pages: 12
<Page 2